Jubilant Life gets USFDA nod for urinary incontinence drug
New Delhi : Jubilant Life Sciences has received the final approval from the US health regulator for Darifenacin Extended-Release Tablets, used for the treatment of urinary incontinence condition.
The company has "received Abbreviated New Drug Application (ANDA) final approval for Darifenacin Extended-Release Tablets, 7.5 mg and 15 mg, the generic version of Enablex of Allergan Plc, which is used for the treatment of urinary incontinence", Jubilant Life Sciences said in a BSE filing.
Jubilant Life Sciences said it has received 6 approvals from the USFDA during the year.
As on June 30, 2016, Jubilant Life Sciences had a total of 70 ANDAs for Oral Solids filed in the US, of which 44 have been approved.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd